

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.*

*Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.*

*This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), and may not be offered or sold in the United States unless registered under the U.S. Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration under the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.*



**Laekna, Inc.**

**來凱醫藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2105)**

## **COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE**

**Sole Overall Coordinator and Sole Placing Agent**



The Board is pleased to announce that all conditions of the Placing have been fulfilled and the completion of the Placing took place on November 27, 2024. Pursuant to the terms and conditions of the Placing Agreement, 17,636,000 Placing Shares have been successfully placed by the Sole Placing Agent to not less than six Places at the Placing Price of HK\$13.36 per Placing Share.

Reference is made to the announcement of Laekna, Inc. (the “**Company**”) dated November 21, 2024 in respect of the placing of new Shares under general mandate (the “**Announcement**”). Unless otherwise stated, the terms used in this announcement shall have the same meaning as defined in the Announcement.

## COMPLETION OF THE PLACING

The Board is pleased to announce that all conditions to the Placing Agreement have been fulfilled and completion of the Placing took place on November 27, 2024. An aggregate of 17,636,000 Placing Shares have been placed by the Sole Placing Agent to not less than six Placees at the Placing Price of HK\$13.36 per Placing Share pursuant to the terms and conditions of the Placing Agreement, representing approximately 4.33% of the issued share capital of the Company as enlarged by the allotment and issue of the Placing Shares immediately upon completion of the Placing.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, the Placees and their respective ultimate beneficial owners are professional, institutional, or other investors who are Independent Third Parties, and none of the Placees have become a substantial shareholder (as defined in the Listing Rules) of the Company as a result of the Placing.

The gross proceeds from the Placing were approximately HK\$235.62 million. The Company received net proceeds from the Placing, after deducting the placing commission and other related expenses and professional fees, of approximately HK\$230.30 million. The Company intends to use the net proceeds for the purposes as disclosed in the paragraph headed "Reasons for the Placing and Use of Proceeds" in the Announcement.

## SHAREHOLDING STRUCTURE OF THE COMPANY UPON COMPLETION OF THE PLACING

The shareholding structure of the Company immediately before and upon completion of the Placing are set out as follows:

	Immediately before completion of the Placing		Immediately upon completion of the Placing	
	<i>Number of Shares held</i>	<i>Approximate % of total Shares in issue</i>	<i>Number of Shares held</i>	<i>Approximate % of total Shares in issue</i>
Dr. LU Chris Xiangyang and entities controlled by him ("Dr. Lu") <sup>(1)</sup>	49,603,870	12.72%	49,603,870	12.16%
Ms. XIE Ling and entities controlled by her ("Ms. Xie") <sup>(2)</sup>	7,500,000	1.92%	7,500,000	1.84%
OrbiMed entities <sup>(3)</sup>	49,148,000	12.60%	49,148,000	12.05%
Public				
— The Placees	—	—	17,636,000	4.33%
— Other public Shareholders	<u>283,848,480</u>	<u>72.76%</u>	<u>283,848,480</u>	<u>69.62%</u>
<b>Total</b>	<b><u>390,100,350</u></b>	<b><u>100.00%</u></b>	<b><u>407,736,350</u></b>	<b><u>100.00%</u></b>

*Notes:*

1. Includes (i) 29,603,870 Shares held beneficially under his name and (ii) 20,000,000 Shares held by Ealex LLC of which Dr. Lu is the settlor and is deemed to be interested in.
2. 7,500,000 Shares are held through Linbell Technology Holdings Limited, which is wholly-owned by Ms. Xie.
3. 49,148,000 Shares are held by OrbiMed Asia Partners III, L.P., a venture capital fund operated by OrbiMed and registered as an exempted limited partnership in the Cayman Islands. The general partner of OrbiMed Asia Partners III, L.P., is OrbiMed Asia GP III, L.P., whose general partner is OrbiMed Advisors III Limited. Accordingly, each of OrbiMed Asia GP III, L.P. and OrbiMed Advisors III Limited is deemed to be interested in the Shares held by OrbiMed Asia Partners III, L.P.

By order of the Board  
**Laekna, Inc.**  
**Dr. LU Chris Xiangyang**  
*Chairman*

Hong Kong, November 27, 2024

*As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.*